Progress toward virtual screening for drug side effects

被引:35
作者
Rockey, WM [1 ]
Elcock, AH [1 ]
机构
[1] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA
来源
PROTEINS-STRUCTURE FUNCTION AND GENETICS | 2002年 / 48卷 / 04期
关键词
D O I
10.1002/prot.10186
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development and application of a computational protocol for conducting virtual screens of drug side interactions is described. A conventional drug-docking algorithm (AutoDock) is used to conduct two separate studies. First, a series of docking simulations is performed by using guanosine diphosphate and adenosine diphosphate as prototype drugs with the goal of successfully differentiating known receptors from a large number of bait receptors. Using the electrostatic energy of the purine ring as a basis for discrimination allows the correct identification of receptors in blind studies with 100% specificity and 94% sensitivity. In a second study, similar methodology is used to investigate the binding of clinically relevant inhibitors (Gleevec, purvalanol A, and hymenialdisine) to a variety of protein kinase targets. Overall, excellent agreement between experimental and predicted preferences for kinase targets is obtained. An important conclusion from the latter study is that homology-modeled structures of putative receptors may reasonably be used as targets for docking when directly solved crystal structures are not available. The prospects for routine application of the methodology as a means of identifying potential side interactions of candidate drugs are discussed. Proteins 2002;48:664-671. (C) 2002Wiley-Liss,lnc.
引用
收藏
页码:664 / 671
页数:8
相关论文
共 37 条
[1]   The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000 [J].
Bairoch, A ;
Apweiler, R .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :45-48
[2]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[3]  
Carlson HA, 2000, MOL PHARMACOL, V57, P213
[4]  
Chen YZ, 2001, PROTEINS, V43, P217, DOI 10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO
[5]  
2-G
[6]   Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate [J].
Davies, TG ;
Tunnah, P ;
Meijer, L ;
Marko, D ;
Eisenbrand, G ;
Endicott, JA ;
Noble, MEM .
STRUCTURE, 2001, 9 (05) :389-397
[7]  
Diller DJ, 2001, PROTEINS, V43, P113, DOI 10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO
[8]  
2-T
[9]  
FLANAGAN A, 2001, BCG FOCUS 2001
[10]   Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors [J].
Gray, NS ;
Wodicka, L ;
Thunnissen, AMWH ;
Norman, TC ;
Kwon, SJ ;
Espinoza, FH ;
Morgan, DO ;
Barnes, G ;
LeClerc, S ;
Meijer, L ;
Kim, SH ;
Lockhart, DJ ;
Schultz, PG .
SCIENCE, 1998, 281 (5376) :533-538